Markets:

Overview

News

Currencies

International

Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

53.27 +0.69 (+1.31%)

Streaming Delayed Price Updated: 12:34 PM EDT, Jul 23, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

A Look Into Healthcare Sector Value Stocks ↗

March 11, 2024

Via Benzinga

Amicus Therapeutics Stock Sees RS Rating Improve To 74 ↗

March 05, 2024

In a welcome move, Amicus Therapeutics stock saw its Relative Strength Rating rise from 69 to 74 on Tuesday.

Via Investor's Business Daily

NASDAQ:ALKS stands out as a stock that provides good value for the fundamentals it showcases. ↗

March 05, 2024

ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

Exploring NASDAQ:ALKS's growth characteristics. ↗

February 28, 2024

Why the growth investor may take a look at NASDAQ:ALKS.

Via Chartmill

Beam Therapeutics Stock Jumps To Higher RS Level On Earnings Beat ↗

February 27, 2024

Beam Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Tuesday, with an upgrade from 73 to 81.

Via Investor's Business Daily

Agios Pharmaceuticals Stock Earns RS Rating Upgrade; Hits Key Benchmark ↗

February 23, 2024

Agios Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating from 65 to 84.

Via Investor's Business Daily

Earnings Scheduled For February 15, 2024 ↗

February 15, 2024

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

Via Benzinga

Alkermes's Earnings Outlook ↗

February 14, 2024

Via Benzinga

Is NASDAQ:ALKS suited for growth investing? ↗

February 07, 2024

Why the growth investor may take a look at NASDAQ:ALKS.

Via Chartmill

NASDAQ:ALKS, an undervalued stock with good fundamentals. ↗

January 19, 2024

Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents.

Via Chartmill

Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for February 2024 ↗

February 21, 2024

Biotech stocks are often at the forefront of innovation. These picks are worth considering for your portfolio for their growth potential.

Via InvestorPlace

Alkermes Stock Gets RS Rating Upgrade; Profits Surge ↗

February 15, 2024

In a welcome move, biotech Alkermes stock saw its Relative Strength Rating improve from 69 to 75 on Thursday.

Via Investor's Business Daily

CRISPR Therapeutics Stock Shows Rising Relative Strength, Hits 90+ ↗

February 13, 2024

CRISPR Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

NASDAQ:ALKS is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. ↗

February 12, 2024

Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents.

Via Chartmill

7 Biotech Stocks Fighting America’s Deadliest Diseases ↗

February 08, 2024

Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship.

Via InvestorPlace

Madrigal Pharmaceuticals Stock Shows Rising Relative Strength ↗

February 06, 2024

A Relative Strength Rating upgrade for Madrigal Pharmaceuticals shows improving technical performance.

Via Investor's Business Daily

Why the growth investor may take a look at ALKERMES PLC (NASDAQ:ALKS). ↗

January 16, 2024

High growth, ROE and beating expectations for NASDAQ:ALKS: growth investors may appreciate this.

Via Chartmill

NASDAQ:ALKS, a growth stock which is not overvalued. ↗

January 10, 2024

Investors seeking growth at a reasonable cost should explore NASDAQ:ALKS.

Via Chartmill

Decoding 5 Analyst Evaluations For Alkermes ↗

January 02, 2024

Via Benzinga

The 3 Best Biotech Stocks to Invest in for Big Gains in 2024 ↗

February 02, 2024

These pivotal biotech stocks for gains are charting the future of medicine and investment growth in 2024 offering powerful returns

Via InvestorPlace

3 Top Pharma Stocks to Buy Now: February 2024 ↗

February 01, 2024

Discover why these three pharma stocks should be on your buy list in February 2024 - they could be your ticket to explosive portfolio growth.

Via InvestorPlace

For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering. ↗

February 01, 2024

Don't overlook ALKERMES PLC (NASDAQ:ALKS)—a stock with solid growth prospects and a reasonable valuation.

Via Chartmill

Axsome Therapeutics Stock Showing Leadership, Earns 91 RS Rating ↗

January 23, 2024

Axsome Therapeutics shows improving price performance, earning an upgrade to its IBD Relative Strength Rating.

Via Investor's Business Daily

Cassava Sciences Stock Continues Showing Rising Relative Strength ↗

January 16, 2024

Cassava Sciences sees its Relative Strength Rating move into the elite 90-plus level.

Via Investor's Business Daily

The 3 Most Undervalued Biotech Stocks to Buy in January ↗

January 15, 2024

These are a number of undervalued biotech companies that investor should possibly look to add to their portfolios.

Via InvestorPlace

Delving into NASDAQ:ALKS's Growth Prospects. ↗

December 26, 2023

High growth, ROE and beating expectations for NASDAQ:ALKS: growth investors may appreciate this.

Via Chartmill

ALKERMES PLC (NASDAQ:ALKS) showing high EPS and FCF growth while beating expectations ↗

December 04, 2023

Why the growth investor may take a look at NASDAQ:ALKS.

Via Chartmill

For those who appreciate value investing, NASDAQ:ALKS is a compelling option with its solid fundamentals. ↗

December 28, 2023

Investors should take notice ofALKERMES PLC (NASDAQ:ALKS)—it offers a great deal for the fundamentals it presents.

Via Chartmill

For those who appreciate growth without the sticker shock, NASDAQ:ALKS is worth considering. ↗

December 20, 2023

Looking for growth without the hefty price tag? Consider ALKERMES PLC (NASDAQ:ALKS).

Via Chartmill

When you look at NASDAQ:ALKS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation. ↗

December 07, 2023

ALKERMES PLC (NASDAQ:ALKS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.